FN2 Earnings Intelligence
Altria Group, Inc. earnings overview
Latest Altria Group, Inc. (MO) earnings intelligence, including the newest scorecard, market reaction, and transcript analysis.
Altria Group, Inc.
The quarter provides partial support for a resilient-demand thesis: Altria raised FY2026 EPS guidance and cited smoke-free portfolio momentum, but the longer-term outlook remains constrained by declining cigarette volumes, consumer pressure, and regulatory execution.
Altria Group, Inc.
Altria delivered a stronger-than-expected Q1 FY2026, with adjusted diluted EPS of $1.32 (up 7.3% YoY) beating consensus by 5.6% and revenue of $4.76B exceeding estimates by 3.9%. The beat was driven by Marlboro's premium share gains (59.5%) and expanding smoke-free penetration via on! PLUS, which reached nationwide availability at ~100,000 stores. Despite the strong start, management reaffirmed rather than raised full-year EPS guidance of $5.56-$5.72, signaling a more conservative H2 outlook and drawing analyst scrutiny. The stock surged 6.5% on the report before drifting -4.2% in subsequent sessions, suggesting the market initially rewarded the beat but reconsidered the unchanged guidance and ongoing macro headwinds. Compared to Q4 2025, where EPS grew 4.4% and the focus was on initial FDA authorizations and the duty drawback program launch, Q1 2026 showed accelerating EPS growth…
Altria Group, Inc.
The analysis supports a mixed but constructive operating thesis: smoke-free product progress, international expansion, and capacity investment provide growth avenues, while maintained guidance and persistent regulatory, competitive, and cost risks limit the strength of the near-term case.
Altria Group, Inc.
Altria's Q3 analysis supports a mixed but constructive operating thesis: smoke-free products, regulatory filings, international partnerships, and cost management provide growth avenues, while declining cigarette volumes and competitive and regulatory uncertainty limit confidence in durable earnings growth.
Altria Group, Inc.
The current analysis supports a constructive but qualified view: oral-tobacco momentum and a raised guidance floor strengthen the near-term operating case, while declining cigarette volumes, regulation, and competition limit confidence in a broader growth thesis.
Altria Group, Inc.
The call supports a mixed view: smoke-free momentum and pricing or brand actions provide growth support, while illicit competition, regulatory constraints and consumer pressure limit confidence in durable earnings growth.
Altria Group, Inc.
Altria's smoke-free portfolio provides a credible growth counterweight to declining cigarette volumes, but the supplied analysis supports a balanced view rather than a clean growth thesis: execution, regulation and illicit-market enforcement remain decisive.
Get the MO recap when the next report posts
One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.